Relmada Therapeutics Inc
RLMD4.544USD
+0.194+4.47%
Market hours （ET）Quotes delayed by 15 min
150.83MMarket Cap
LossP/E TTM
More Details of Relmada Therapeutics Inc Company
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Relmada Therapeutics Inc Info
Ticker SymbolRLMD
Company nameRelmada Therapeutics Inc
IPO dateMar 03, 2014
CEOTraversa (Sergio C)
Number of employees17
Security typeOrdinary Share
Fiscal year-endMar 03
Address2222 Ponce De Leon Blvd. 3Rd Floor
CityCORAL GABLES
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33134
Phone16468763459
Websitehttps://www.relmada.com/
Ticker SymbolRLMD
IPO dateMar 03, 2014
CEOTraversa (Sergio C)
Company Executives of Relmada Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Charles Ence
Mr. Charles Ence
Chief Accounting, Compliance Officer
Chief Accounting, Compliance Officer
403.93K
+50.76%
Dr. Paul Kelly ,
Dr. Paul Kelly ,
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Mr. John Glasspool
Mr. John Glasspool
Independent Director
Independent Director
--
--
Mr. Sergio C. Traversa
Mr. Sergio C. Traversa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Maged S. Shenouda
Mr. Maged S. Shenouda
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Mr. Tim McCarthy
Mr. Tim McCarthy
Investor Relations
Investor Relations
--
--
Ms. Fabiana Fedeli
Ms. Fabiana Fedeli
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Charles Ence
Mr. Charles Ence
Chief Accounting, Compliance Officer
Chief Accounting, Compliance Officer
403.93K
+50.76%
Dr. Paul Kelly ,
Dr. Paul Kelly ,
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Mr. John Glasspool
Mr. John Glasspool
Independent Director
Independent Director
--
--
Mr. Sergio C. Traversa
Mr. Sergio C. Traversa
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Maged S. Shenouda
Mr. Maged S. Shenouda
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Squadron Capital Management LLC
4.50%
Trigone Pharma Ltd
4.11%
VR Adviser, LLC
3.10%
Kotler (Kevin)
2.59%
Ikarian Capital LLC
2.51%
Other
83.19%
Shareholders
Shareholders
Proportion
Squadron Capital Management LLC
4.50%
Trigone Pharma Ltd
4.11%
VR Adviser, LLC
3.10%
Kotler (Kevin)
2.59%
Ikarian Capital LLC
2.51%
Other
83.19%
Shareholder Types
Shareholders
Proportion
Investment Advisor
7.57%
Individual Investor
6.69%
Investment Advisor/Hedge Fund
4.35%
Corporation
4.11%
Hedge Fund
3.33%
Venture Capital
3.10%
Research Firm
0.20%
Other
70.64%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
168
11.43M
15.59%
-4.28M
2025Q2
178
17.22M
51.89%
-1.52M
2025Q1
208
14.72M
44.35%
-4.49M
2024Q4
230
11.64M
38.59%
-9.19M
2024Q3
292
15.66M
51.91%
-17.50M
2024Q2
305
16.59M
54.98%
-17.06M
2024Q1
309
17.32M
57.39%
-15.84M
2023Q4
309
16.26M
54.01%
-15.41M
2023Q3
315
17.65M
58.65%
-15.70M
2023Q2
316
18.87M
62.69%
-16.71M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Squadron Capital Management LLC
3.30M
9.94%
+1.25M
+60.90%
Jun 30, 2025
Trigone Pharma Ltd
3.02M
9.09%
+3.02M
--
Mar 27, 2025
VR Adviser, LLC
2.27M
6.84%
+2.27M
--
Mar 27, 2025
Kotler (Kevin)
1.90M
5.72%
--
--
Mar 27, 2025
Traversa (Sergio)
1.00M
3.01%
+265.98K
+36.24%
Aug 28, 2025
Shenouda (Maged R)
288.33K
0.87%
+200.00K
+226.41%
May 20, 2025
Driehaus Capital Management, LLC
740.01K
2.23%
+740.01K
--
Jun 30, 2025
Acadian Asset Management LLC
619.48K
1.87%
-608.45K
-49.55%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Psychedelics ETF
5.81%
Avantis US Small Cap Equity ETF
0%
Fidelity Enhanced Small Cap ETF
0%
iShares Micro-Cap ETF
0%
AdvisorShares Psychedelics ETF
Proportion5.81%
Avantis US Small Cap Equity ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Relmada Therapeutics Inc?
The top five shareholders of Relmada Therapeutics Inc are:
Squadron Capital Management LLC holds 3.30M shares, accounting for 9.94% of the total shares.
Trigone Pharma Ltd holds 3.02M shares, accounting for 9.09% of the total shares.
VR Adviser, LLC holds 2.27M shares, accounting for 6.84% of the total shares.
Kotler (Kevin) holds 1.90M shares, accounting for 5.72% of the total shares.
Traversa (Sergio) holds 1.00M shares, accounting for 3.01% of the total shares.
Squadron Capital Management LLC holds 3.30M shares, accounting for 9.94% of the total shares.
Trigone Pharma Ltd holds 3.02M shares, accounting for 9.09% of the total shares.
VR Adviser, LLC holds 2.27M shares, accounting for 6.84% of the total shares.
Kotler (Kevin) holds 1.90M shares, accounting for 5.72% of the total shares.
Traversa (Sergio) holds 1.00M shares, accounting for 3.01% of the total shares.
What are the top three shareholder types of Relmada Therapeutics Inc?
The top three shareholder types of Relmada Therapeutics Inc are:
Squadron Capital Management LLC
Trigone Pharma Ltd
VR Adviser, LLC
Squadron Capital Management LLC
Trigone Pharma Ltd
VR Adviser, LLC
How many institutions hold shares of Relmada Therapeutics Inc (RLMD)?
As of 2025Q3, 168 institutions hold shares of Relmada Therapeutics Inc, with a combined market value of approximately 11.43M, accounting for 15.59% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -36.30%.
What is the biggest source of revenue for Relmada Therapeutics Inc?
In --, the -- business generated the highest revenue for Relmada Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
